Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

Research and Innovation Action · Running

ELR-SCAR A novel multi-functional elastin-like recombinant hydrogel for the prevention of scar tissue formation following a myocardial infarction: ""ELR-SCAR""""

Coordinator
University of Galway, Ireland
Runs
1 December 2022 to 30 November 2026
Status
Running
EU funding
€4.5m
Total cost
€4.5m
Partners
8 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101091766

What the project is doing

In the project's own words, from its summary on CORDIS.

The ELR SCAR project aims to complete preclinical validation of a novel biomaterial, an elastin-like recombinant (ELR) hydrogel, to prevent scar tissue formation in the heart following myocardial infarction (MI), commonly called a heart attack. MI is the endpoint of ischaemic heart disease (IHD). In Europe, the highest rates of IHD worldwide equal ~26.5 million patients. Standards of care interventions after MI have serious limitations in treatment efficacy (many patients are still at risk of developing heart failure) and patient safety.

There is a clear medical need for new treatment solutions that prevent scar tissue formation and irreversible cardiac remodelling. Our robust preclinical dataset so far indicates that the ELR hydrogel has this promising functionality via multiple unique characteristics: it provides selective cell adhesion to the endocardium, providing a barrier to scar tissue formation; it offers high biospecificity to the ischaemic microenvironment, and it has an enhanced biodegradability, allowing for safe disintegration in the body.

To facilitate endocardial delivery of the ELR hydrogel, we will develop a minimally invasive endocardial catheter in this project. Both components (hydrogel + catheter) will be advanced to the preparedness level for a first-in-human (FIH) validation study for the application as therapeutic intervention post-MI (to be performed after the project). In addition, we will develop the regulatory and IPR strategies in preparation for this clinical validation step.

Considering the high societal impact of ischaemic heart disease (IHD) and MI, we will also develop a solid health economic evaluation of possible savings and patient benefits. ELR-SCAR will transform and fundamentally improve clinical practice, resulting in reducing the enormous burden that MI and its leading cause, IHD, place on society and the individual patient.

Topics

Who is involved

OrganisationCityCountryRole
University of GalwayGalwayIrelandCoordinator
Cardiovascular Research Center Aalst VzwAalstBelgiumParticipant
Hemex Germany GmbHLorrachGermanyParticipant
Technical Proteins Nanobiotechnology SLValladolidSpainParticipant
Boston Scientific LimitedGalwayIrelandParticipant
Lietuvos Sveikatos Mokslu UniversitetasKaunasLithuaniaParticipant
Catalyze B.V.Amsterdam-DuivendrechtNetherlandsParticipant
Slaski Uniwersytet Medyczny W KatowicachKatowicePolandParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI